Musculoskeletal pain and its impact on prognosis following acute coronary syndrome or stroke: A linked electronic health record cohort study (2023)
Journal Article
Mason, K. J., Jordan, K. P., Heron, N., Edwards, J. J., Bailey, J., Achana, F. A., …Marshall, M. (2023). Musculoskeletal pain and its impact on prognosis following acute coronary syndrome or stroke: A linked electronic health record cohort study. Musculoskeletal Care, 21(3), 749-762. https://doi.org/10.1002/msc.1748

OBJECTIVE: Musculoskeletal painful conditions are a risk factor for cardiovascular disease (CVD), but less is known about whether musculoskeletal pain also worsens prognosis from CVD. The objective was to determine whether patients with musculoskelet... Read More about Musculoskeletal pain and its impact on prognosis following acute coronary syndrome or stroke: A linked electronic health record cohort study.

Musculoskeletal pain and its impact on rates of hospitalisation and mortality in cancer: a linked electronic health record cohort study (MSKCOM) (2022)
Presentation / Conference
Mason, K., Bailey, J., Heron, N., Marshall, M., Achana, F., Chen, Y., …Jordan, K. (2022, July). Musculoskeletal pain and its impact on rates of hospitalisation and mortality in cancer: a linked electronic health record cohort study (MSKCOM). Paper presented at SAPC ASM 2022 - UCLan 50th Annual Scientific Meeting, University of Central Lancashire, UK

Background: Patients with painful musculoskeletal conditions have an increased risk of developing cancer, but less is known about whether this impacts on the longer-term cancer prognosis. This study aims to determine whether patients with painful mus... Read More about Musculoskeletal pain and its impact on rates of hospitalisation and mortality in cancer: a linked electronic health record cohort study (MSKCOM).

P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study (2022)
Journal Article
Mason, K. J., Jordan, K. P., Achana, F. A., Bailey, J., Chen, Y., Frisher, M., …Edwards, J. J. (2022). P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study. Rheumatology, 61(S1), https://doi.org/10.1093/rheumatology/keac133.180

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background/Aims</jats:title> <jats:p>There is some evidence of an increased risk of cardiovascular disease in patients with painful musculoskeletal conditions, but it is unclear if musculoskele... Read More about P181 Musculoskeletal pain and prognosis of acute coronary syndrome and cerebrovascular accident: a linked electronic health record cohort study.

Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM) (2021)
Presentation / Conference
Mallen, Mason, K., Frisher, Mamas, Jordan, Marshall, …White. (2021, November). Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM). Presented at SAPC North 2021, Virtual

Background: There is evidence that painful musculoskeletal conditions are associated with increased risk of cardiovascular disease, but less is known about whether this impacts on prognosis of cardiovascular disease. The aim was to determine whether... Read More about Musculoskeletal pain and its impact on prognosis following hospitalisation for acute coronary syndrome or cerebrovascular accident: a linked electronic health record cohort study (MSKCOM).

Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. (2021)
Journal Article
Mahil, S., Yates, M., Langan, S., Yiu, Z., Tsakok, T., Dand, N., …study groups, P. C. (2021). Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. British Journal of Dermatology, 185(1), https://doi.org/10.1111/bjd.19755

BACKGROUND: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatm... Read More about Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey..

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. (2020)
Journal Article
Iskandar, I., Warren, R., Lunt, M., Mason, K., Evans, I., McElhone, K., …Ashcroft, D. (2020). Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatology, 157(1), 66-73. https://doi.org/10.1001/jamadermatol.2020.4202

Importance: Treatments for psoriasis may be less effective in everyday practice than in clinical trials. Emulating a target trial using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) can provide t... Read More about Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register..

Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study (2020)
Journal Article
Mahil, S. K., Dand, N., Mason, K. J., Yiu, Z. Z. . N., Tsakok, T., Meynell, F., …study group, P. (2021). Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study. Journal of Allergy and Clinical Immunology, 147(1), 60-71. https://doi.org/10.1016/j.jaci.2020.10.007

BACKGROUND: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. OBJECTIVE: Characterize the course of COVID-19 in psoriasis and identify fa... Read More about Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study.

Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2020). Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 34(4), 467 - 467. https://doi.org/10.1111/jdv.16018

Background
The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.

Objectives
To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and stroke) i... Read More about Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2019). Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), 769 - 778. https://doi.org/10.1111/jdv.16018

BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in pa... Read More about Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study..

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2017)
Journal Article
Iskandar, I. Y., Warren, R. B., Lunt, M., Mason, K. J., Evans, I., McElhone, K., …Griffiths, C. E. (2018). Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(4), 775 - 784. https://doi.org/10.1016/j.jid.2017.09.044

Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse event... Read More about Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..